Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 11:21 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 224 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Diuretics Clear all

Conditions: Fluid Overload, Heart Failure Acute
Interventions: Metolazone 60 minutes prior to furosemide, Metolazone concurrently with furosemide; Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 89 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Heart Failure NYHA Class II, Heart Failure NYHA Class III, Heart Failure
Interventions: Cordella™ Pulmonary Artery Sensor System; Device
Lead sponsor: Endotronix, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,750 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2033
U.S. locations: 45
States / cities: Phoenix, Arizona • Los Angeles, California • San Francisco, California + 35 more

Conditions: Bronchopulmonary Dysplasia, Hyponatremia on Diuretics
Interventions: Sodium supplementation, Fluid restriction; Procedure
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 4 Weeks to 6 Months
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Heart Failure, CHF
Interventions: IV loop diuretic, NxStage System One; Drug · Device
Lead sponsor: NxStage Medical; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Congestive Heart Failure
Interventions: Noninvasive Hemodynamic Measurement System; Diagnostic Test
Lead sponsor: Rodin Scientific LLC; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Eating Disorder Not Otherwise Specified
Interventions: Screening Questionnaire, Pre-Intervention Questionnaires (~10 minutes), SSI (Single-session intervention (~30 minutes) Active arm, SSI (Single-session intervention (~30 minutes) control arm, End-of-Intervention Questionnaires (~5 minutes); Behavioral
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years to 22 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Acute Decompensated Heart Failure
Interventions: Reprieve System, furosemide infusion; Device · Drug
Lead sponsor: Reprieve Cardiovascular, Inc; Industry
Eligibility: 22 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 35
States / cities: Irvine, California • Long Beach, California • Sacramento, California + 28 more

Conditions: Heart Failure, Heart Failure Acute, Acute Cardiac Pulmonary Edema, Acute Cardiac Failure
Interventions: LUS-guided strategy-of-care, Usual Care, Intravenous Loop Diuretic, Vasodilator, Non invasive Ventilation (NIV); Other · Drug · Device
Lead sponsor: Indiana University; Other
Eligibility: 21 Years and older
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 6
States / cities: Indianapolis, Indiana • Detroit, Michigan • Cleveland, Ohio + 2 more

Conditions: Hypertension
Interventions: Loop diuretics, thiazides, dihydropyridines, Telmisartan; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 55 Years and older
Enrollment: 40,048 participants
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Acute Mountain Sickness
Interventions: Acetazolamide; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 105 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Stanford, California

Conditions: Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Unusual Cancers of Childhood
Interventions: anti-thymocyte globulin, filgrastim, busulfan, carmustine, cyclophosphamide, cyclosporine, cytarabine, etoposide, fludarabine phosphate, melphalan, methotrexate, methylprednisolone, mycophenolate mofetil, tacrolimus, peripheral blood stem cell transplantation, umbilical cord blood transplantation, radiation therapy; Biological · Drug · Procedure + 1 more
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: Up to 60 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Acute Kidney Injury
Interventions: Conservative dialysis strategy, TIW dialysis strategy; Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 100 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Cardiomyopathy, Congestive Heart Failure
Interventions: Tolvaptan 30 mg + IV Diuretics, Metolazone 5 mg + IV Diuretics, 2.5 times the Diuretics Dose; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Liver Failure
Interventions: Vasopressin, Normal saline placebo; Drug
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years to 80 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Hypertension
Interventions: Darusentan, Guanfacine, Darusentan Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 35 Years to 80 Years
Enrollment: 849 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 87
States / cities: Birmingham, Alabama • Huntsville, Alabama • Montgomery, Alabama + 70 more

Conditions: Acute Mountain Sickness
Interventions: Ibuprofen, Acetazolamide; Drug
Lead sponsor: Grant S Lipman; Other
Eligibility: 18 Years to 65 Years
Enrollment: 92 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Bishop, California

Conditions: Hypertension (HTN)
Interventions: Combination Product: FDC of spironolactone and ER torsemide, Combination Product: Stabilized doses of loop diuretic and finerenone; Drug
Lead sponsor: Sarfez Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Vienna, Virginia

Conditions: Heart Failure
Interventions: Shared-management diuretic titration guided by remote PA pressure monitoring; Other
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 40 Years to 90 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Menomonee Falls, Wisconsin

Conditions: Hypertension
Interventions: Study#1: chlorthalidone (CTD), titrated dose, Study #1: spironolactone (SP), titrated dose, Study# 2 chlorthalidone (CTD), fixed dose, Study# 2 spironolactone (SP), fixed dose, Study# 2 irbsesartan (IR), fixed dose; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 166 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2013
U.S. locations: 2
States / cities: Dallas, Texas

Conditions: Heart Failure, Ventricular Dysfunction, Sudden Death, Sudden Cardiac Arrest, Ventricular Tachycardia, Ventricular Fibrillation
Interventions: wearable defibrillator (LifeVest); Device
Lead sponsor: Zoll Medical Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Pre-Eclampsia, Hypertension in Pregnancy, Pregnancy Complications, Hypertension, Pregnancy-Induced
Interventions: Furosemide, Placebo; Drug · Other
Lead sponsor: Melanie Maykin, MD; Other
Eligibility: 18 Years and older · Female only
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Honolulu, Hawaii

Conditions: Cognitive Decline, Blood Pressure, Hypertension
Interventions: Clinical Support Decision Tool; Other
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 70 Years and older
Enrollment: 4,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Primary Aldosteronism, Hypertension
Interventions: Eplerenone; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 85 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Diabetic Nephropathy
Interventions: Lisinopril, Nifedipine, Simvastatin; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1993 – 1999
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Search by objective public record fields.

Diuretic Effect of Metolazone Pre-dosing Versus Concurrent Dosing

PROACTIVE-HF-2 Trial Heart Failure NYHA Class II and III

Management of Hyponatremia in Preterm Infants on Diuretics

Extracorporeal Ultrafiltration (UF) vs. Usual and Customary Care for Patients With Severe Heart Failure (HF)

Hemodynamic Assessment in Acute Decompensated Heart Failure

A Single-session Intervention Adaptation of the Habit Framework for the Prevention of Eating Disorders

Fluid Management of Acute Decompensated Heart Failure Subjects Treated With Reprieve System (FASTR-II) (IDE-G210258)

B-lines Lung Ultrasound Guided ED Management of Acute Heart Failure Pilot Trial

Replication of the TRANSCEND Antihypertensive Trial in Healthcare Claims Data

Sickness Evaluation at Altitude With Acetazolamide at Relative Dosages

Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer

Recovery After Dialysis-Requiring Acute Kidney Injury

AiDing Diuresis wIth Tolvaptan (ADD-IT)

Study to Evaluate if the Drug Vasopressin Protects the Kidneys for Patients Undergoing Liver Transplant

DORADO-AC - Optimized Doses of Darusentan as Compared to an Active Control in Resistant Hypertension

Altitude Sickness Prevention With Ibuprofen Relative to Acetazolamide and Treatment Efficacy

A Study Comparing the Clinical Benefit of Finerenone Versus a Fixed Dose Combination (FDC) of Extended-Release Torsemide and Spironolactone in Patients With Hypertension and Chronic Kidney Disease

Patient-Executed, Clinician-Confirmed Diuretic Titration in Pulmonary Artery Pressure-Guided Heart Failure (SURPASS-HF)

Effects of Thiazide Diuretics on Sympathetic Nervous System in Hypertension

Study of the Wearable Defibrillator in Heart-Failure Patients

Furosemide vs. Placebo for Severe Antepartum Hypertension

Preventing Cognitive Decline by Reducing BP Target Trial

Cardiovascular Manifestations of MR Activation in Primary Aldosteronism: Pilot Clinical Study

Drugs for High Blood Pressure and High Cholesterol in American Indians With Type 2 Diabetes